Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well as for contract manufacturing. OLON owns 5 manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees while INFA Group, with more than 400 employees, has 2 manufacturing sites in Italy, Labochim and Sifavitor, and 1 in Spain, Derivados Químicos.

Jiangsu Yikai Medical Equipment Co., Ltd., established on 2013-12-05, The scope of business includes two types of6866Production of medical polymer materials and products,processing,Sales(Operate according to the business scope and period listed in the license);medical catheter,Production of Class I Medical Devices,processing,Sales;Self-operated and agent import and export business of the above commodities.(Except for goods that are restricted by the state to be operated by enterprises or prohibited from import and export);daily mask(non-medical)Production;daily mask(non-medical)Sales;Production of Class II Medical Devices;Wholesale of Class II Medical Devices;Retailing of Class II Medical Devices;(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. engages in pharmaceutical research and development, manufacturing and sales, pharmaceutical modern logistics, health industry, and medical manufacturing and sales of beauty product. It offers Chinese patent drug, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, antibiotic drugs, medical cosmetology, and scientific research equipment. The company was founded on December 31, 1992 and is headquartered in Hangzhou, China.

Kyoto Biken Laboratories, Inc. manufactures veterinary vaccines. It specializes in bovine, porcine, poultry, and plant vaccines. The firm��s business activities include research and development, manufacturing, laboratory diagnosis for field specimens, quality control, after sales validation, and packaging and shipment. The company was founded in June 1948 and is headquartered in Uji, Japan.

Mylan Laboratories Ltd. manufactures and supplies active pharmaceutical ingredients. The firm operates through two segments: Pharmaceuticals and Medical Supplies. It manufactures and supplies generic and branded generic formulations to various markets, including North America, Europe and Asia Pacific. Mylan Laboratories was founded on November 29, 1984 and is headquartered in Hyderabad, India.

Chengdu Yatu Biotechnology Co. Ltd. is a company headquartered in China. The firm operates a research and development process company for bio-medicines.

Specializes in pharmaceutical products such as cephalosporin and penicillin

China State Institute of Pharmaceutical Industry is a Chinese company located in Shanghai and ultimately controlled by the Government of China. The firm regulates pharmaceutical companies.

Chongxing Daxin Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company in China. It produces finished dosages and intermediates of cardio-vascular, antibiotics, immunosuppressant and plasma volume expander. The company was founded in 1941 and is headquartered in Chongqing, CN.

Lunan New Times Biotechnology Co., Ltd., established on 2007-03-15, Business scope includes biotechnology products,Pharmaceutical Intermediates,Raw materials and preparations,Healthy food,food,Research and Development of Cosmetics,production and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Shanghai Laiyi Biological Drug Research and Development Center Co., Ltd., established on 2001-12-03, The scope of business includes the research of biopharmaceuticals,Technical services in development and related fields,technology development,technical consulting,technology transfer. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Zhejiang Pharmaceutical Co., Ltd. Xinchang Pharmaceutical Factory, established on 1999-02-13, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;food production;food business;Hazardous Chemical Production;Food additive production;Feed additive production;road freight transport(Does not contain dangerous goods);road freight transport(Contains dangerous goods)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Feed Additive Sales;Chemical product sales(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).(Engage in business activities within the business scope of the head office)

Shandong Lubei Pharmaceutical Co., Ltd., established on 1999-12-06, Business range includes tablet,hard capsule,Lysozyme,Hyaluronidase API manufacturing,Sales;Sales of health food;Self-support import and export business,Except for products that are restricted or prohibited by the state.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kaneka Corp. engages in the manufacture and sale of chemicals, synthetic resins, and plastics. It operates through the following segments: Material Solutions, Quality of Life Solutions, Health Care Solutions, Nutrition Solutions and Others. The Material Solutions segment covers biodegradable polymers, materials that support the development of social infrastructure and mobility which includes the weight reduction and fuel efficiency improvement. The Quality of Life Solutions segment handles energy saving needs such as housing and living infrastructure, and development of Internet of things (IoT) and artificial intelligence (AI). The Health Care Solutions segment offers solutions through the fusion of devices and medicines, and develops healthcare business based on biopharmaceuticals and regenerative and cellular medicines. The Nutrition Solutions segment provides materials and supplement solutions to food production support in livestock and fishery industries. The Others segment provides agency services for property and life insurance. The company was founded on September 1, 1949 and is headquartered in Osaka, Japan.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.

Peking University Medical Management Co., Ltd., established on 2021-10-29, Business scope includes general items:hospital management;Health Consulting Services(Does not include medical services);Remote Health Management Services;Information Consulting Service(Not including licensing information consulting services);Business Management Consulting;Financial Advisory;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Sales of Class II Medical Devices;Production of protective equipment for medical personnel(Ι class medical device);Sales of Class I Medical Devices;Production of Class I Medical Devices;Engage in investment activities with own funds;Information Technology Consulting Services;Data processing and storage support services;internet data service;data processing services;Information system integration service;electronics sales;Hardware retail;Wholesale of hardware products;Machinery sales;General merchandise sales;Sporting Goods and Equipment Retailing;Retailing of computer software, hardware and auxiliary equipment;Machinery and Equipment Leasing;Import and export;Technology Import and Export;Import and export agency;Information system operation and maintenance services;Engineering Management Services;internet sales(Except for products that require a license for sale).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of protective equipment for medical personnel(Class II medical device);Class III medical device business;Production of Class II Medical Devices;Production of Class III Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are approved by relevant departments,documents or permits shall prevail)

New Founder Holdings Development Co., Ltd., established on 2021-10-21, Business scope includes general items:Engage in investment activities with own funds;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;culture,Manufacturing of office equipment;Manufacturing of computer software, hardware and peripheral equipment;Communication equipment manufacturing;Instrument Manufacturing;Financial Advisory;electronics sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Instrument sales;Machinery sales;Metal Ore Sales;Sales of non-metallic minerals and products;Gold and Silver Products Sales;Metal Material Sales;Sales of building materials;Chemical product sales(No licensed chemical products);Import and export;Import and export agency;Technology Import and Export;Loading and unloading;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);packaging service;property management.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Real estate development and management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are approved by relevant departments,documents or permits shall prevail)

Peking University Medical was established in 2003 and was jointly established by Peking University and Founder Group. Relying on Peking University's rich expert resources, advanced management experience and perfect medical teaching and research system, as well as the strong financial strength and industrial integration ability of Founder Group, Peking University Medical Center is committed to medical service and pharmaceutical industry with "quality + innovation" as its core strategy. , innovation and venture capital fields, and strive to build management capacity and output capacity with new technology innovation incubator modern hospital, the Internet to build a sound medical and health insurance systems, innovative R & D capabilities of large international health technology companies in the pharmaceutical sector.